A nucleoside reverse transcriptase inhibitor
Related Products
Isomer(s)
36037Apricitabine
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Lamivudine

Item No. 18514

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
4-amino-1-[(2R,5S)-2-(hydroxymethyl)1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone
CAS Number
134678-17-4
Synonyms
  • (-)-BCH 189
  • 3TC
  • 2’,3’-dideoxy-3’-Thiacytidine
Molecular Formula
C8H11N3O3S
Formula Weight
229.3
Purity
≥98%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 20 mg/mlDMSO: 20 mg/mlEthanol: 0.5 mg/mlPBS (pH 7.2): 3 mg/ml
λmax
233, 271 nm
SMILES
OC[C@@H]1O[C@H](N2C(N=C(N)C=C2)=O)CS1
InChi Code
InChI=1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1
InChi Key
JTEGQNOMFQHVDC-NKWVEPMBSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    500 mg

    $57

    Add

    1 g

    $96

    Add

    5 g

    $445

    Add

    10 g

    $778

    Add
    Cayman Chemical
    Neutrophil Biology Wall Poster

    Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.

    DOWNLOAD NOW
    Product Description

    Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI).1 It is phosphorylated intracellularly to its active form lamivudine-5'-triphosphate by the successive actions of deoxycytidine kinase, cytidine monophosphate kinase, and deoxycytidine monophosphate kinase. It reduces HIV-1 p24 antigen levels in the culture supernatant of human peripheral blood lymphocytes infected with laboratory-adapted HIV-1 strains, indicating inhibition of HIV replication, with IC50 values ranging from 0.0025 to 0.09 µM.2 Lamivudine inhibits syncytium formation between various CD4+ cell lines and several strains of HIV-1 or HIV-2 (IC50s = 0.014-0.61 µM). It reduces serum viral titers in a woodchuck model of chronic hepatitis B virus (HBV) infection when administered at doses of 40 or 200 mg/kg.3 Formulations containing lamivudine have been used in the treatment of HIV and HBV infections.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Johnson, M.A., Moore, K.H., Yuen, G.J., et al. Clinical pharmacokinetics of lamivudine. Clin. Pharmacokinet. 36(1), 41-66 (1999).

    2. Coates, J.A., Cammack, N., Jenkinson, H.J., et al. (–)-2'-Deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob. Agents Chemother. 36(4), 733-739 (1992).

    3. Mason, W.S., Cullen, J., Moraleda, G., et al. Lamivudine therapy of WHV-infected woodchucks. Virology 245(1), 18-32 (1998).